Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Regeneron Wins BARDA Contract | Contract Pharma

What are you searching for?

Sign in
Breaking News

Regeneron Wins BARDA Contract

To manufacture antibody therapies for the potential prevention and treatment of MERS

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Regeneron Pharmaceuticals, Inc. has entered an agreement with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS) to manufacture and study two antibody therapies for the potential prevention and treatment of Middle East Respiratory Syndrome (MERS) using its VelociGene and VelocImmune technologies.

HHS will provide as much as $8.9 million of funding to support fill and finish of the antibodies for human use, the preparation and submission of an Investigational New Drug application with the U.S. FDA, and a National Institutes of Health-conducted clinical trial in healthy volunteers. Currently there are no approved medicines or vaccines to treat or prevent MERS, which causes severe respiratory tract infections and is associated with high death rates.

“Regeneron has built a unique rapid response platform to address emerging infectious disease threats. In addition to the programs in MERS and Ebola that we are advancing with BARDA, we are also quickly progressing a preclinical program targeting the Zika virus,” said Neil Stahl, Ph.D., Executive Vice President of Research and Development at Regeneron. “We are committed to partnering with the government and other organizations to swiftly address these emerging public health emergencies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics